High seroprevalence against SARS-CoV-2 in non-vaccinated patients with inflammatory bowel disease from Northern India.
5-Aminosalicylic acid
Antigen-S1RBD
COVID-19
Crohn’s disease
Immunosuppression
Seropositive
Seroprevalence
Steroids
Thiopurines
Ulcerative colitis
Vaccine
Journal
Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
ISSN: 0975-0711
Titre abrégé: Indian J Gastroenterol
Pays: India
ID NLM: 8409436
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
09
03
2022
accepted:
07
11
2022
medline:
28
3
2023
pubmed:
5
2
2023
entrez:
4
2
2023
Statut:
ppublish
Résumé
The information on seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among patients with inflammatory bowel disease (IBD) and its comparison to healthy controls is sparse. We compared the seroprevalence rates in patients with IBD and healthy controls (HCs). Patients with IBD and HCs (contact of patients) underwent SARS-CoV-2 antibody testing (chemiluminescent immunoassay: Siemens kit IgG against antigen-S1RBD) between July 2020 and April 2021. Information on demography, disease characteristics, drug history and past history of SARS-CoV-2 infection were noted. Patients on 5-aminosalicylic acid or no treatment were considered not on immunosuppressants and those who had received steroids, thiopurines or methotrexate within six months of inclusion were considered being on immunosuppressants. A total of 235 patients (51.9%, males; mean age, 38.7 ± 12.4 years; median disease duration, 60 months [interquartile range, IQR: 36-120]) (ulcerative colitis [UC]: 69.4%, Crohn's disease [CD]: 28.9%, IBD unclassified [IBDU]: 1.7%) and 73 HCs (mean age, 39.6 ± 10.9 years, 80% males) were enrolled. Of the 235 patients, 128 (54.5%) patients were on immunosuppressants and 107 (45.5%) were not on immunosuppressants. Seventy-four (31.5%) patients were seropositive, of which two (0.9%) had previous history of SARS-CoV-2 infection and none received coronavirus disease-19 (COVID-19) vaccine. Seroprevalence between IBD patients and HCs (32% vs. 27%, p > 0.05) and between patients with and without immunosuppressants (28.1% vs. 36%, p > 0.05) was similar. Age, gender, disease type, duration and activity in the last six months; and medication use were similar between patients with positive and negative serology. There was a progressive increase in seroprevalence from July 2020 to April 2021. Up to 1/3rd of patients with IBD were seropositive for immunoglobulin G (IgG) SARS-Cov-2 antibody indicating high seroprevalence in patients with IBD from Northern India.
Sections du résumé
BACKGROUND
The information on seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among patients with inflammatory bowel disease (IBD) and its comparison to healthy controls is sparse. We compared the seroprevalence rates in patients with IBD and healthy controls (HCs).
METHODS
Patients with IBD and HCs (contact of patients) underwent SARS-CoV-2 antibody testing (chemiluminescent immunoassay: Siemens kit IgG against antigen-S1RBD) between July 2020 and April 2021. Information on demography, disease characteristics, drug history and past history of SARS-CoV-2 infection were noted. Patients on 5-aminosalicylic acid or no treatment were considered not on immunosuppressants and those who had received steroids, thiopurines or methotrexate within six months of inclusion were considered being on immunosuppressants.
RESULTS
A total of 235 patients (51.9%, males; mean age, 38.7 ± 12.4 years; median disease duration, 60 months [interquartile range, IQR: 36-120]) (ulcerative colitis [UC]: 69.4%, Crohn's disease [CD]: 28.9%, IBD unclassified [IBDU]: 1.7%) and 73 HCs (mean age, 39.6 ± 10.9 years, 80% males) were enrolled. Of the 235 patients, 128 (54.5%) patients were on immunosuppressants and 107 (45.5%) were not on immunosuppressants. Seventy-four (31.5%) patients were seropositive, of which two (0.9%) had previous history of SARS-CoV-2 infection and none received coronavirus disease-19 (COVID-19) vaccine. Seroprevalence between IBD patients and HCs (32% vs. 27%, p > 0.05) and between patients with and without immunosuppressants (28.1% vs. 36%, p > 0.05) was similar. Age, gender, disease type, duration and activity in the last six months; and medication use were similar between patients with positive and negative serology. There was a progressive increase in seroprevalence from July 2020 to April 2021.
CONCLUSION
Up to 1/3rd of patients with IBD were seropositive for immunoglobulin G (IgG) SARS-Cov-2 antibody indicating high seroprevalence in patients with IBD from Northern India.
Identifiants
pubmed: 36738383
doi: 10.1007/s12664-022-01310-y
pii: 10.1007/s12664-022-01310-y
pmc: PMC9898695
doi:
Substances chimiques
Immunosuppressive Agents
0
Antibodies, Viral
0
Immunoglobulin G
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
70-78Subventions
Organisme : All-India Institute of Medical Sciences
ID : A-COVID34
Informations de copyright
© 2023. Indian Society of Gastroenterology.
Références
Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–9.
doi: 10.1038/s41586-020-2008-3
pubmed: 32015508
pmcid: 7094943
Singh P, Ananthakrishnan A, Ahuja V. Pivot to Asia: inflammatory bowel disease burden. Intest Res. 2017;15:138–41.
doi: 10.5217/ir.2017.15.1.138
pubmed: 28239326
pmcid: 5323305
Kedia S, Ahuja V. Epidemiology of inflammatory bowel disease in India: the great shift east. Inflamm Intest Dis. 2017;2:102–15.
doi: 10.1159/000465522
pubmed: 30018961
pmcid: 5988149
Ahuja V, Tandon RK. Inflammatory bowel disease in the Asia-Pacific area: a comparison with developed countries and regional differences. J Dig Dis. 2010;11:134–47.
doi: 10.1111/j.1751-2980.2010.00429.x
pubmed: 20579217
Kucharzik T, Ellul P, Greuter T, et al. ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. J Crohns Colitis. 2021;15:879–913.
doi: 10.1093/ecco-jcc/jjab052
pubmed: 33730753
Rubin DT, Abreu MT, Rai V, et al. Management of patients with Crohn’s disease and ulcerative colitis during the coronavirus disease-2019 pandemic: results of an international meeting. Gastroenterology. 2020;159:6-13.e6.
doi: 10.1053/j.gastro.2020.04.002
pubmed: 32272113
Seydoux E, Homad LJ, MacCamy AJ, et al. Analysis of a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with limited somatic mutation. Immunity. 2020;53:98-105.e5.
doi: 10.1016/j.immuni.2020.06.001
pubmed: 32561270
pmcid: 7276322
Long Q-X, Liu B-Z, Deng H-J, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26:845–8.
doi: 10.1038/s41591-020-0897-1
pubmed: 32350462
Caini S, Bellerba F, Corso F, et al. Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies up to 25 April 2020 and public health implications. Euro Surveill. 2020;25:2000980.
doi: 10.2807/1560-7917.ES.2020.25.23.2000980
pubmed: 32553061
pmcid: 7403641
Berte’ R, Mazza S, Stefanucci MR, et al. Seroprevalence of SARS-CoV2 in IBD patients treated with biologic therapy. J Crohns Colitis. 2021;15:864–8.
doi: 10.1093/ecco-jcc/jjaa237
pubmed: 33211810
Freeman MC, Rapsinski GJ, Zilla ML, Wheeler SE. Immunocompromised seroprevalence and course of illness of SARS-CoV-2 in one pediatric quaternary care center. A J Pediatric Infect Dis Soc. 2021;10:426–31.
doi: 10.1093/jpids/piaa123
pubmed: 33049042
Simon D, Tascilar K, Krönke G, et al. Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. Nat Commun. 2020;11:3774.
Norsa L, Cosimo P, Indriolo A, Sansotta N, D’Antiga L, Callegaro A. Asymptomatic severe acute respiratory syndrome coronavirus 2 infection in patients with inflammatory bowel disease under biologic treatment. Gastroenterology. 2020;159:2229-31.e2.
Kennedy NA, Goodhand JR, Bewshea C, et al. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut. 2021;70:865–75.
doi: 10.1136/gutjnl-2021-324388
pubmed: 33753421
Scucchi L, Neri B, Sarmati L, et al. Low prevalence of SARS-CoV-2 infection in inflammatory bowel disease. Eur Rev Med Pharmacol Sci. 2021;25:2418–24.
pubmed: 33755981
McGregor CG, Adams A, Sadler R, et al. Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic. Gut. 2021;70:2398–400.
doi: 10.1136/gutjnl-2021-324116
pubmed: 33579788
Łodyga M, Maciejewska K, Eder P, et al. Inflammatory bowel disease is associated with higher seroprevalence rates of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Pol Arch Intern Med. 2021;131:226–32.
pubmed: 33544564
Bossa F, Carparelli S, Latiano A, et al. Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs. Dig Liver Dis. 2021;53:277–82.
doi: 10.1016/j.dld.2020.12.120
pubmed: 33423942
pmcid: 7834247
Dailey J, Kozhaya L, Dogan M, et al. Antibody responses to SARS-CoV-2 after infection or vaccination in children and young adults with inflammatory bowel disease. Inflamm Bowel Dis. 2022;28:1019–26.
doi: 10.1093/ibd/izab207
pubmed: 34528661
Chanchlani N, Lin S, Chee D, et al. Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11 422 biologic-treated patients. J Crohns Colitis. 2022;16:389–97.
doi: 10.1093/ecco-jcc/jjab153
pubmed: 34473254
Di Ruscio M, Lunardi G, Buonfrate D, et al. A seroprevalence study of anti-SARS-CoV-2 antibodies in patients with inflammatory bowel disease during the second wave of the COVID-19 pandemic in Italy. Medicina (Kaunas). 2021;57:1048.
doi: 10.3390/medicina57101048
pubmed: 34684085
Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13:144–64.
Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19 Suppl A:5A-36A.
doi: 10.1155/2005/269076
pubmed: 16151544
Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut. 1998;43:29–32.
doi: 10.1136/gut.43.1.29
pubmed: 9771402
pmcid: 1727189
Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70:439–44.
doi: 10.1016/S0016-5085(76)80163-1
pubmed: 1248701
Murhekar MV, Bhatnagar T, Selvaraju S, et al. Prevalence of SARS-CoV-2 infection in India: findings from the national serosurvey, May-June 2020. Indian J Med Res. 2020;152:48–60.
doi: 10.4103/ijmr.IJMR_3290_20
pubmed: 32952144
pmcid: 7853249
Murhekar MV, Bhatnagar T, Selvaraju S, et al. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey. Lancet Glob Health. 2021;9:e257–66.
doi: 10.1016/S2214-109X(20)30544-1
pubmed: 33515512
pmcid: 7906675
Murhekar MV, Bhatnagar T, Thangaraj JWV, et al. SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020-January 2021. Int J Infect Dis. 2021;108:145–55.
doi: 10.1016/j.ijid.2021.05.040
pubmed: 34022338
pmcid: 8132496
Murhekar MV, Bhatnagar T, Thangaraj JWV, et al. Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: a population-based cross-sectional study. PLoS Med. 2021;18: e1003877.
doi: 10.1371/journal.pmed.1003877
pubmed: 34890407
pmcid: 8726494
Jahan N, Brahma A, Kumar MS, et al. Seroprevalence of IgG antibodies against SARS-CoV-2 in India, March 2020 to August 2021: a systematic review and meta-analysis. Int J Infect Dis. 2021;116:59–67.
doi: 10.1016/j.ijid.2021.12.353
pubmed: 34968773
pmcid: 8712428
National SARS-CoV-2 Serology Assay Evaluation Group. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infect Dis. 2020;20:1390–400.
doi: 10.1016/S1473-3099(20)30634-4